Strength Training on GLP-1 Medications: What the Science Says About Protecting Your Muscle

Here is a number worth sitting with: men using semaglutide or tirzepatide lose roughly 6 kilograms of lean mass during a typical 68-to-72-week treatment course. That figure — drawn from a 2025 review in Obesity Reviews — represents approximately 20 years of age-related muscle loss compressed into little more than a year. For men who care about how they look, how they perform, and how long they stay functional and independent, that statistic is impossible to ignore.

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound) have genuinely changed the treatment landscape for obesity and metabolic disease. The weight loss results from clinical trials are historically unprecedented — 15 to 24 percent reductions in body weight, alongside meaningful improvements in blood pressure, cholesterol, blood glucose, and insulin sensitivity. But the same caloric suppression that drives fat loss does not discriminate at the tissue level. Muscle goes too, and it goes fast. The good news is that this is a solvable problem — and resistance training is the most powerful tool available to solve it.

Why GLP-1 Medications Threaten Muscle Mass

To understand the muscle loss problem, it helps to understand what these medications are actually doing. GLP-1 receptor agonists work primarily by mimicking the incretin hormone glucagon-like peptide-1, which suppresses appetite, slows gastric emptying, and reduces overall caloric intake. The result is a steep and sustained caloric deficit — the kind that, in any context, causes the body to shed both fat and lean tissue. A 2024 narrative review in Diabetes Care put it plainly: incretin-based therapies cause rapid and significant loss of lean mass comparable to a decade or more of aging, roughly 10 percent of total muscle mass across trials.

This matters beyond aesthetics. Muscle tissue is metabolically active. It is the primary site of glucose disposal, meaning more muscle mass generally translates to better insulin sensitivity and a more resilient metabolic rate. Men who lose substantial muscle while on GLP-1 therapy set themselves up for a particularly harsh outcome if they ever discontinue the medication — a lower metabolic floor, a higher proportion of body fat, and an accelerated return of the weight they lost. The Obesity Reviews authors describe this as a risk of weight cycling with compromised quality of life and adverse long-term outcomes. The muscle you preserve during treatment is essentially insurance against the rebound.

The situation is especially serious for older men. A 2026 analysis in the British Journal of Pharmacology found that while shorter-term trials of semaglutide showed relative preservation of handgrip strength despite lean tissue losses, longitudinal data in older adults with type 2 diabetes told a different story — reductions in handgrip strength and accelerated sarcopenia with prolonged use. For men over 50 already navigating age-related muscle decline, adding the compounding effect of GLP-1-driven lean mass loss without a counteracting strategy is a genuine clinical risk.

The Case for Resistance Training as a Non-Negotiable Add-On

The science here is not subtle. Supervised resistance training lasting more than 10 weeks produces approximately 3 kilograms of lean mass gain and around 25 percent improvements in strength in both men and women, according to the Diabetes Care review. That is essentially half the lean mass loss from GLP-1 therapy recovered through consistent lifting. When you frame it that way, resistance training is not a nice-to-have adjunct — it is a structural component of any responsible GLP-1 protocol.

Mechanick and colleagues were direct in their recommendations: all patients receiving incretin-mimetic drugs for obesity should participate in comprehensive treatment programs that include resistance training. This is not hedged language. The authors note that concurrent physical activity, especially resistance training, has been shown to effectively minimize loss of muscle mass and function during weight reduction therapy. Combined with adequate protein intake, it represents the two-lever system for protecting lean tissue during aggressive fat loss.

From a practical standpoint, men on GLP-1 medications should be training with resistance a minimum of two to three times per week, emphasizing compound movements that recruit large muscle groups — squats, deadlifts, rows, presses, hip hinges. Progressive overload matters here just as it does in any hypertrophy program. The muscle-preserving stimulus needs to be sufficient to signal retention; going through the motions with light resistance will not provide the necessary anabolic drive. Intensity and consistency are what move the needle. The appetite suppression from GLP-1 therapy can make training feel harder on lower caloric intake, so managing workout timing — training when energy is highest, typically in the morning or several hours after a meal — becomes a meaningful practical consideration.

Protein intake is the other side of this equation, and it interacts directly with training outcomes. A 2026 clinical nutrition review proposed daily protein targets of at least 1.2 grams per kilogram of body weight, rising to 1.6 grams per kilogram in appropriate adults, with per-meal targets of 0.3 to 0.4 grams per kilogram and roughly 2.5 to 3 grams of leucine per sitting to maximally stimulate muscle protein synthesis. The challenge is that GLP-1 medications suppress appetite broadly — men often struggle to hit protein targets simply because they are not hungry. Prioritizing protein-dense foods first at each meal, before carbohydrates or fats, is a practical approach that ensures the most important macronutrient gets consumed even when total intake is limited. Leucine-rich sources — eggs, chicken, Greek yogurt, whey protein, cottage cheese — should anchor the diet.

Micronutrient status also deserves attention. The same review notes that baseline micronutrient inadequacies are common in people with obesity and can be worsened by the reduced intake and gastrointestinal side effects — nausea, vomiting — that accompany GLP-1 therapy. Vitamin D, B12, iron, folate, zinc, and thiamine all warrant monitoring. These are not peripheral concerns; deficiencies in vitamin D and zinc are directly linked to impaired muscle function and recovery.

For older men specifically, the integration of resistance training and adequate protein during GLP-1 therapy is particularly well-supported. A 2025 precision obesity medicine framework noted that liraglutide combined with resistance training and adequate protein intake can preserve lean mass in older and sarcopenic individuals — a finding that underscores the synergy between the pharmacologic and behavioral components of treatment.

What This Means For You

GLP-1 medications are a powerful tool for fat loss and metabolic improvement, but they are not a complete program on their own. The research is unambiguous: without deliberate effort to preserve muscle through resistance training and sufficient protein intake, men on semaglutide or tirzepatide risk trading fat for a body composition that is lighter but metabolically weaker, physically frailer, and harder to maintain. That is not an outcome worth accepting when the countermeasures are this well-established.

Whether you are on a GLP-1 medication, eating in a caloric deficit the traditional way, or simply trying to hold onto muscle as you age, the underlying principle is identical: lift consistently, eat enough protein, and treat muscle preservation as the foundation everything else is built on. The medication changes the appetite. The training changes the outcome.